Full-Time

Associate – Patient Materials Operations

Mss

Posted on 7/3/2025

Deadline 7/13/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Compensation Overview

$57.9k - $70.1k/yr

+ Incentive Cash + Stock Opportunities

Junior, Mid

Company Historically Provides H1B Sponsorship

Summit, NJ, USA

In Person

Onsite Day Shift role, Sunday - Wednesday, 6 a.m. - 4:30 p.m.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • Bachelor’s degree. An equivalent combination of education, experience and training may substitute.
  • Or Associate/ Medical Technical degree and 2 years of Manufacturing or Operations experience.
  • Or High School diploma/GED and 4 years of Manufacturing or Operations experience.
Responsibilities
  • Performs tasks for Cell Therapy products to support product Value Stream outputs according to Current Good Manufacturing Practices (cGMP’s) following the current, approved Standard Operating Procedures (SOPs) and Work Instructions (WIs).
  • Maintains timing according to the production schedule to ensure on-time logistics.
  • Performs apheresis receipt of patient materials and prepares final product shipments for couriers.
  • Executes receipt and discard of ex-US Peripheral Blood Mononuclear Cells (PBMC) and ex-US Cryopreserved Material (CMAT).
  • Supports Sample Retrieval, Sample Movements, and Sample Storage.​
  • Supports transfers of Manufactured Goods to off-site facility.
  • Supports manual and electronic batch record executions, deviation investigations, and closure of CAPAs.
  • Ensures all documentation is correct and addresses procedural/documentation errors expeditiously and effectively.
  • Work with management to ensure adequately trained personnel are available to perform all manufacturing activities.
  • Records patient material handling data and information in a clear, concise, format according to proper GDPs.
  • Able to problem solve with minimal supervision.
  • Works in a team based, cross-functional environment to complete tasks required by shift schedule.
  • Must be able to work in an environment with blood derived components.
  • Available to work OT when business requires.
  • Willing to work staggered day shift hours.

Bristol Myers Squibb (BMS) is a biopharmaceutical company that develops and delivers medicines for serious diseases, focusing on oncology, immunology, and cardiovascular conditions. The company invests heavily in research and development to create new drugs, which are sold to hospitals and healthcare providers after receiving regulatory approval. BMS also produces affordable generic medications and supports the development of biosimilars to increase access to healthcare. With a commitment to sustainability and corporate responsibility, BMS aims to improve patient outcomes and build trust with stakeholders.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Chris Shibutani's appointment may drive strategic growth and innovation at BMS.
  • Advancements in targeted protein degradation enhance therapeutic offerings in oncology.
  • Partnership with BioNTech could provide a competitive edge against Merck's Keytruda.

What critics are saying

  • Antitrust litigation over Pomalyst could impact BMS's market position in oncology.
  • Reliance on real-world data presents challenges in data quality and implementation.
  • High costs and technical challenges in space research could affect treatment feasibility.

What makes Bristol Myers Squibb unique

  • BMS collaborates with BioNTech for next-gen cancer immunotherapy, enhancing oncology portfolio.
  • Focus on real-world data strategies could lead to faster drug market entry.
  • Developing bone disease treatments in space positions BMS as a leader in innovative research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

ISS National Lab
Jul 7th, 2025
This is Not the Time to Cut Space-enabled Medical Research

Bristol-Myers Squibb is developing novel bone disease treatments in space, and the National Stem Cell Foundation is studying 3D brain organoids derived from patients with Parkinson's disease in microgravity to observe disease progression more rapidly with the aim of identifying potential biomarkers for early diagnosis and therapeutic targets.

The Pharma Letter
Jun 26th, 2025
Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst

Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst.

Unlearn
Jun 24th, 2025
The Best 15 Minutes You'll Spend on Clinical Trials Today

At the 2025 "Digital Breakthrough for Pharma" Summit hosted by Bristol Myers Squibb, Unlearn's co-founder and machine learning scientist, Aaron Smith, took the stage to explain exactly how that vision is now a reality.

ROI-NJ
Jun 13th, 2025
Bristol Myers Squibb Names Shibutani As Evp, Chief Strategy Officer

Bristol Myers Squibb (BMS) this week appointed Chris Shibutani as executive vice president, chief strategy officer, effective immediately. Shibutani’s role is a new position on the BMS leadership team. The announcement was made on a LinkedIn post.Shibutani will lead the development and advancement of the company’s long-term strategic plan, collaborating across the enterprise to drive innovation and growth. He brings more than 25 years of experience in the financial services industry covering global pharmaceutical, biotechnology and medical device industries.Prior to BMS, Shibutani served as managing director in the global investment research division at Goldman Sachs. Previous roles include senior analyst positions at Hambrecht & Quist, Cowen, UBS, and J.P. Morgan.Before his career in finance, Shibutani was a physician trained in anesthesiology and critical care medicine at Massachusetts General Hospital and practiced at Memorial Sloan Kettering Cancer Center

PharmaData
Jun 13th, 2025
Bristol Myers Squibb Highlights Targeted Protein Degradation Data, Including CELMoD Agents, at EHA 2025

Bristol Myers Squibb highlights targeted protein degradation advances, including CELMoD agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy.

INACTIVE